{"id":16785,"date":"2024-03-13T14:21:24","date_gmt":"2024-03-13T05:21:24","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=16785"},"modified":"2026-01-08T16:02:39","modified_gmt":"2026-01-08T07:02:39","slug":"results","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/shinryoka\/nyusen\/results\/","title":{"rendered":"\u4e73\u817a\u5916\u79d1 \u81e8\u5e8a\u7814\u7a76\u767a\u8868\u5b9f\u7e3e"},"content":{"rendered":"\n

\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6<\/h2>\n\n\n\n

\u4ee4\u548c6\u5e74\u5ea6<\/h3>\n\n\n\n

\u3010\u81e8\u5e8a\u7814\u7a76\u3011<\/p>\n\n\n\n

    \n
  1. HER2\u967d\u6027ER\u9670\u6027\u4e73\u764c\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b50HSD17B4\u9ad8\u30e1\u30c1\u30eb\u5316\u306e\u6709\u7528\u6027\u8a55\u4fa1\u8a66\u9a13\u30002017\u5e74\u304b\u30892024\u5e74<\/li>\n\n\n\n
  2. \u30a8\u30b9\u30c8\u30ed\u30b2\u30f3\u53d7\u5bb9\u4f53\u967d\u6027\u30fb\u4f4e\u30ea\u30b9\u30af\u975e\u6d78\u6f64\u6027\u4e73\u764c\u306b\u5bfe\u3059\u308b\u975e\u5207\u9664\uff0b\u5185\u5206\u6ccc\u7642\u6cd5\u306e\u6709\u7528\u6027\u306b\u95a2\u3059\u308b\u5358\u7fa4\u691c\u8a3c\u7684\u8a66\u9a13\uff08JCOG1505\uff092017\u5e74\u304b\u30892032\u5e74<\/li>\n\n\n\n
  3. \u9ad8\u9f62\u8005HER2\u967d\u6027\u9032\u884c\u4e73\u764c\u306b\u5bfe\u3059\u308bT-DM1\u7642\u6cd5\u3068\u30da\u30eb\u30c4\u30ba\u30de\u30d6\uff0b\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\uff0b\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u7642\u6cd5\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u7b2cIII\u76f8\u8a66\u9a13 (JCOG1607)\u30002018\u5e74\u304b\u30892030\u5e74<\/li>\n\n\n\n
  4. \u85ac\u7269\u7642\u6cd5\u306b\u3088\u308a\u81e8\u5e8a\u7684\u5b8c\u5168\u594f\u52b9\u304c\u5f97\u3089\u308c\u305fHR\u9670\u6027HER 2 \u967d\u6027\u539f\u767a\u4e73\u764c\u306b\u5bfe\u3059\u308b\u975e\u5207\u9664\u7642\u6cd5\u306e\u6709\u7528\u6027\u306b\u95a2\u3059\u308b\u5358\u7fa4\u691c\u8a3c\u7684\u8a66\u9a13\uff08JCOG1806\uff09\u30002019\u5e74\u304b\u30892028\u5e74<\/li>\n\n\n\n
  5. \u9589\u7d4c\u5f8c\u30db\u30eb\u30e2\u30f3\u53d7\u5bb9\u4f53\u967d\u6027\u5207\u9664\u4e0d\u80fd\u304a\u3088\u3073\u8ee2\u79fb\u30fb\u518d\u767a\u4e73\u764c\u306b\u5bfe\u3059\u308b \u30d1\u30eb\u30dc\u30b7\u30af\u30ea\u30d6\u7642\u6cd5\u306e\u89b3\u5bdf\u7814\u7a76\u30002019\u5e74\u304b\u30892024\u5e74<\/li>\n\n\n\n
  6. \u9032\u884c\u30fb\u518d\u767a\u4e73\u764c\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u30d7\u30ed\u30b8\u30a7\u30af\u30c8Advanced Breast Cancer Database (ABCD) project\u30002020\u5e741\u6708\u304b\u30892029\u5e7412\u6708<\/li>\n\n\n\n
  7. \u30aa\u30ea\u30b4\u8ee2\u79fb\u3092\u6709\u3059\u308b\u9032\u884c\u4e73\u764c\u306b\u5bfe\u3059\u308b\u6839\u6cbb\u7684\u5c40\u6240\u7642\u6cd5\u8ffd\u52a0\u306e\u610f\u7fa9\u3092\u691c\u8a3c\u3059\u308b\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u3000JCOG2110\u30002023\u5e74\u304b\u30892032\u5e74<\/li>\n<\/ol>\n\n\n\n

    \u4ee4\u548c5\u5e74\u5ea6<\/h3>\n\n\n\n

    \u3010\u82f1\u6587\u539f\u8457\u3011<\/p>\n\n\n\n

      \n
    1. Iwase T\u3001Saji S\u3001Iijima K\u3001Higaki K\u3001Ohtani S\u3001Sato Y\u3001Hozumi Y\u3001Hasegawa Y\u3001Yanagita Y\u3001Takei H\u3001Tanaka M\u3001 Masuoka H\u3001Tanabe M\u3001Egawa C\u3001Komoike Y\u3001Nakamura T\u3001Ohtsu H\u3001Mukai H. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. J Clin Oncol. 2023 Jun 20;41(18):3329-3338.<\/li>\n\n\n\n
    2. Morishita A\u3001Hozumi Y\u3001Ishii H\u3001Hokazono Y\u3001Manuel Yosei Kikuchi C\u3001Shimasaki M\u3001Itaya M\u3001 Oura M\u3001Kuriki K\u3001Hishida A\u3001Seki G. Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep. 2023 Jan 5;2023(1):22-0269<\/li>\n<\/ol>\n\n\n\n

      \u3010\u548c\u6587\u3011<\/p>\n\n\n\n

        \n
      1. \u7530\u53e3 \u771f\u5e0c\u3001\u77f3\u4e95 \u4f38\u5c1a\u3001\u5317\u539f \u7f8e\u7531\u7d00\u3001\u9234\u6728 \u8056\u4e00. \u4e73\u304c\u3093\u8853\u5f8c\u65e9\u671f\u306e\u80a9\u95a2\u7bc0\u53ef\u52d5\u57df\u8a13\u7df4\u304c\u8853\u5f8c\u5408\u4f75\u75c7\u306b\u4e0e\u3048\u308b\u5f71\u97ff. \u8328\u57ce\u770c\u7acb\u75c5\u9662\u533b\u5b66\u96d1\u8a8c40\u5dfb1\u53f7 Page1-8(2023.10)<\/li>\n<\/ol>\n\n\n\n

        \u4ee4\u548c4\u5e74\u5ea6<\/h3>\n\n\n\n

        \u3010\u82f1\u6587\u539f\u8457\u3011<\/p>\n\n\n\n

          \n
        1. Morishita A,  <\/sup>Hozumi Y, Ishii H, Hokazono Y, Manuel C, Kikuchi Y, Shimasaki M, Itaya M, Oura M, Kuniki K, Hishida A, Seki G. Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep 2023 Jan 1;2023:22-0269.<\/li>\n<\/ol>\n\n\n\n

          \u3010\u548c\u6587\u3011<\/p>\n\n\n\n

            \n
          1. \u5cf6\u7530 \u6d69\u548c, \u5927\u795e \u6b63\u5b8f, \u9234\u6728 \u5609\u6cbb, \u4e09\u6a4b \u5f70\u4e00, \u7a42\u7a4d \u5eb7\u592b, \u9234\u6728 \u7f8e\u52a0. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u5358\u5264\u6295\u4e0e\u60a3\u8005\u306b\u304a\u3051\u308binfusion reaction\u767a\u73fe\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u30ea\u30b9\u30af\u56e0\u5b50\u306b\u95a2\u3059\u308b\u8abf\u67fb. \u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c58\u5dfb11\u53f7 1298-1302<\/li>\n<\/ol>\n\n\n\n

            \u4ee4\u548c3\u5e74\u5ea6<\/h3>\n\n\n\n

            \u3010\u82f1\u6587\u539f\u8457\u3011<\/p>\n\n\n\n

              \n
            1. Kitahara M, Hozumi Y, Machinaga M, Hayashi Y. A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1<\/em> and BRCA2<\/em>.Case Rep Oncol. 2021. 14(3):1645-1651.<\/li>\n\n\n\n
            2. Mukai H, Uemura Y, Akabane H, Watanabe T, Park Y, Takahashi M, Sagara Y, Nishimura R, Takashima T, Fujisawa T, Hozumi Y, Kawahara T. Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer..Br J Cancer. 2021 125(9):1217-1225.<\/li>\n\n\n\n
            3. Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai.  A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. H.Clin Breast Cancer. 2021;21(5):450-457.<\/li>\n\n\n\n
            4. Yamaguchi T, Hozumi Y, Sagara Y, Takahashi M, Yoneyama K, Fujisawa T, Osumi S, Akabane H, Nishimura R, Mieno MN, Mukai H. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. Surg Oncol. 2021.36:51-55<\/li>\n<\/ol>\n\n\n\n

              \u3010\u548c\u6587\u3011<\/p>\n\n\n\n

                \n
              1. \u753a\u6c38\u5e79\u6708\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7af9\u5185\u76f4\u4eba\u3001\u6e21\u908a\u4f91\u5948\u3001\u6589\u85e4\u4ec1\u662d\u3001\u98ef\u5cf6\u9054\u751f\u3001\u7a42\u7a4d\u5eb7\u592b, \u9032\u884c\u4e73\u764c\u306e\u6cbb\u7642\u4e2d\u306b\u60aa\u6027\u30ea\u30f3\u30d1\u816b\u3068\u5927\u8178\u764c\u3092\u767a\u75c7\u3057\u305f\u4e09\u91cd\u8907\u764c\u306e1 \u4f8b\u3002\u764c\u3068\u5316\u5b66\u7642\u6cd5 48\u5dfb, 11\u53f7, 1397 – 1399 2021<\/li>\n\n\n\n
              2. \u85e4\u539f\u5f69\u7e54\u3001\u5742\u6771\u88d5\u5b50\u3001\u4e0a\u7530\u6587\u3001\u5e02\u5ca1\u6075\u7f8e\u9999\u3001\u90fd\u5cf6\u7531\u5e0c\u5b50\u3001\u4e95\u53e3\u7814\u5b50\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u539f\u5c1a\u4eba\uff0e\u4e73\u764c\u8ee2\u79fb\u306b\u4f34\u3046\u6c34\u814e\u75c7\u306b\u5bfe\u3057\u7a4d\u6975\u7684\u4ecb\u5165\u3092\u884c\u3063\u305f8\u75c7\u4f8b\u306e\u691c\u8a0e\uff0e\u4e73\u764c\u306e\u81e8\u5e8a\uff0e36\u5dfb4\u53f7\u3000295-300\u30012021\u5e74<\/li>\n<\/ol>\n\n\n\n

                \u4ee4\u548c2\u5e74\u5ea6<\/h3>\n\n\n\n

                \u3010\u82f1\u6587\u539f\u8457\u3011<\/p>\n\n\n\n

                  \n
                1. Yamaguchi T, Hozumi Y, Sagara Y, Takahashi M, Yoneyama K, Fujisawa T, Osumi S, Akabane H, Nishimura R, Mieno MN, Mukai H. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. Surg Oncol. 36:51-55, 2020. Epub ahead of print. PMID: 33310293.<\/li>\n\n\n\n
                2. Kitahara M, Hozumi Y, Takeuchi N, Ichinohe S, Fujiwara S, Machinaga M, Saitoh H, Iijima T. Distant Metastasis after Surgery for Encapsulated Papillary Carcinoma of the Breast: A Case Report. Case Rep Oncol.13:1196-1201. 2020<\/li>\n\n\n\n
                3. Yamashita S, Hattori N, Fujii S, Yamaguchi T, Takahashi M, Hozumi Y, Kogawa T, El-Omar O, Liu YY, Arai N, Mori A, Higashimoto H, Ushijima T, Mukai H. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Sci Rep. 10:15530. 2020<\/li>\n\n\n\n
                4. Kitahara M, Hozumi Y, Takeuchi N, Ichinohe S, Machinaga M, Iijima T. Invasive Cancer Confined to the Nipple of the Conserved Breast: A Case Report. Case Rep Oncol. 13:1125-1130. 2020.<\/li>\n\n\n\n
                5. Ohsumi S, Mukai H, Takahashi M, Hozumi Y, Akabane H, Park Y, Tokunaga E,Takashima T, Watanabe T, Sagara Y, Kaneko T, Ohashi Y. Factors affecting enrollment in randomized controlled trials conducted for patients with metastatic breast cancer. Jpn J Clin Oncol. 50:873-2020<\/li>\n\n\n\n
                6. Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, Duijm-de Carpentier M, Rutgers EJT, Seynaeve C, Bartlett JMS, Vannetzel JM, Rea DW, Hasenburg A, Paridaens R, Markopoulos CJ, Hozumi Y, Portielje JEA, Kroep JR, van de Velde CJH, Liefers GJ. Overestimation of Late Distant Recurrences in High- Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. J Clin Oncol. 38:3273-3281.2020. Epub 2020 Jul 24.<\/li>\n\n\n\n
                7. Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. Br J Cancer. 122:1747-1753. 2020. Epub 2020 Apr 2..<\/li>\n\n\n\n
                8. Matsunuma R, Watanabe T, Hozumi Y, Koizumi K, Ito Y, Maruyama S, Ogura H, Goto K, Mori H, Sawai N, Shiiya N. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer. Breast Cancer. 27:819-827. 2020. Epub 2020 Mar 6.<\/li>\n<\/ol>\n\n\n\n

                  \u3010\u548c\u6587\u7dcf\u8aac\u3011<\/p>\n\n\n\n

                    \n
                  1. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u5185\u7530\u6587\u5f66\u3001\u5c0f\u5cf6\u5bdb\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u67f3\u5ddd\u5fb9\uff0e\u6b6f\u79d1\u533b\u5e2b\u306e\u305f\u3081\u306e\u5185\u79d1\u5b66\u8b1b\u5ea7 \u5168\u8eab\u7ba1\u7406\u30fb\u5168\u8eab\u75be\u60a3\u3092\u898b\u636e\u3048\u305f\u88dc\u7db4\u6cbb\u7642\u306e\u30b9\u30b9\u30e1\uff08\u7b2c 31 \u56de\uff09\u300c\u304c\u3093\u306e\u60a3\u8005\u3055\u3093\u306b\u6b6f\u79d1\u6cbb\u7642\u304c\u5fc5\u8981\u306b\u306a\u3063\u305f\u3089\uff1f\u6b6f\u79d1\u533b\u9662\u3067\u306e\u5bfe\u5fdc\u306f\uff1f\u300d\u88dc\u7db4\u81e8\u5e8a 53\uff1app191-212\u30012020<\/li>\n<\/ol>\n\n\n\n

                    \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                      \n
                    1. \u5317\u539f\u7f8e\u7531\u7d00, \u7a42\u7a4d\u5eb7\u592b, \u4e00\u6238\u601c\u5b50, \u7af9\u5185\u76f4\u4eba, \u6e21\u908a\u4f91\u5948, \u9f4b\u85e4\u4ec1\u662d, \u98ef\u5d8b\u9054\u751f, \u9ad8\u6a4b\u77e5\u5b50, \u5712\u539f\u4e00\u6075. \u30aa\u30f3\u30b3\u30bf\u30a4\u30d7 DX \u4e73\u304c\u3093\u518d\u767a\u30b9\u30b3\u30a2\u691c\u67fb\u3092\u5b9f\u65bd\u3057\u305f 30 \u4f8b\u306e\u691c\u8a0e \u7b2c 28 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a2020 \u5e74 10 \u6708 Web<\/li>\n\n\n\n
                    2. \u7af9\u5185\u76f4\u4eba, \u5317\u539f\u7f8e\u7531\u7d00, \u6589\u85e4\u4ec1\u662d, \u98ef\u5d8b\u9054\u751f, \u7a42\u7a4d\u5eb7\u592b\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u809d\u751f\u691c\u3092\u65bd\u884c\u3057\u305f\u4e73\u764c\u809d\u8ee2\u79fb 4 \u4f8b\u306e\u691c\u8a0e \u7b2c 28 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a 2020 \u5e74 10 \u6708 Web<\/li>\n\n\n\n
                    3. \u753a\u6c38\u5e79\u6708, \u5317\u539f\u7f8e\u7531\u7d00, \u7af9\u5185\u76f4\u4eba, \u6e21\u908a\u4f91\u5948, \u658e\u85e4\u4ec1\u662d, \u98ef\u5d8b\u9054\u751f, \u7a42\u7a4d\u5eb7\u592b\uff0e\u9032\u884c\u4e73\u764c\u306e\u6cbb\u7642\u4e2d\u306b\u60aa\u6027\u30ea\u30f3\u30d1\u816b\u3068\u5927\u8178\u764c\u3092\u767a\u75c7\u3057\u305f\u591a\u91cd\u764c\u306e\u4e00\u4f8b \u7b2c 28 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a 2020 \u5e74 10 \u6708Web<\/li>\n\n\n\n
                    4. \u5317\u539f\u7f8e\u7531\u7d00, \u7a42\u7a4d\u5eb7\u592b, \u7af9\u5185\u76f4\u4eba\uff0e\u30a8\u30b9\u30c8\u30ed\u30b2\u30f3\u30ec\u30bb\u30d7\u30bf\u30fc\u967d\u6027\u4e73\u764c\u306b\u304a\u3051\u308b\u8853\u524d\u30db\u30eb\u30e2\u30f3\u7642\u6cd5\u306e\u691c\u8a0e \u7b2c 120 \u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a 2020 \u5e74 8 \u6708 \u6a2a\u6d5c\u5e02\uff08Web \u3068\u306e\u30cf\u30a4\u30d6\u30ea\u30c3\u30c8\u958b\u50ac\uff09<\/li>\n<\/ol>\n\n\n\n

                      \u4ee4\u548c\u5143\u5e74\u5ea6<\/h3>\n\n\n\n

                      \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                        \n
                      1. Kitahara M, Hozumi Y, Nakamura A, Tachi K, Saitoh H, Iijima T. HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer. Case Rep Oncol. 12, 473-479, 2019.<\/li>\n\n\n\n
                      2. Ohno S, Mukai H, Narui K, Hozumi Y, Miyoshi Y, Yoshino H, Doihara H, Suto A, Tamura M, Morimoto T, Zaha H, Chishima T, Nishimura R, Ishikawa T, Uemura Y, Ohashi Y. Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat. 176. 631-635, 2019<\/li>\n<\/ol>\n\n\n\n

                        \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                          \n
                        1. Hozumi Y, Ohsumi S, Mukai H, Takahashi M, Akabane H, Park Y, Tokunaga E, Takashima T, Watanabe T, Sagara Y, Kaneko T, Ohashi Y. Factors affecting enrolment in randomised controlled trials of Japanese patients with metastatic breast cancer. San Antonio Breast Cancer Symposium, Dec 11th San Antonio, TX, USA<\/li>\n\n\n\n
                        2. Matsunuma R, Watanabe T, Hozumi Y, Koizumi K, Ito Y, Fujita H, Ogura H, Goto K, Mori H, Sawai N, Shiiya N. An efficacy and safety trial of preoperative chemo-endocrine therapy in luminal b-like (HER2-negative) breast cancer San Antonio Breast Cancer Symposium, 2019. Dec 13th San Antonio, TX, USA<\/li>\n\n\n\n
                        3. \u7530\u5730\u4f73\u5948\u3001\u4e2d\u6751\u6587\u9999\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b Palbociclib \u306e\u4f7f\u7528\u7d4c\u9a13\uff0e\u7b2c 27 \u56de\u65e5\u672c \u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7\uff08\u6771\u4eac)<\/li>\n\n\n\n
                        4. \u4e2d\u6751\u6587\u9999\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u7530\u5730\u4f73\u5948\u3001\u5317\u539f\u7f8e\u7531\u7d00\uff0e\u5185\u5206\u6ccc\u7642\u6cd5\u4e2d\u306b FDG \u96c6\u7a4d\u3092\u4f34\u3046\u53f3\u5927\u80f8\u7b4b\u5185\u826f\u6027\u816b \u760d\u3092\u8a8d\u3081\u305f\u53f3\u4e73\u764c\u306e\u4e00\u4f8b\uff0e\u7b2c 27 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7(\u6771\u4eac)<\/li>\n\n\n\n
                        5. \u5712\u539f\u4e00\u6075\u3001\u67cf \u5f69\u7e54\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7530\u5730\u4f73\u5948\u3001\u4e2d\u6751\u6587\u9999\u3001\u7389\u6728\u7fa9\u96c4\u3001\u6797 \u5b8f\u3001\u9234\u6728\u8056\u4e00\uff0e\u4e73\u764c\u9aa8\u8ee2\u79fb\u306b\u7740\u76ee\u3057\u305f\u30c1\u30fc\u30e0\u533b\u7642\u306b\u304a\u3051\u308b\u73fe\u72b6\u3068\u8ab2\u984c\uff0e\u7b2c 27 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7(\u6771\u4eac)<\/li>\n\n\n\n
                        6. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u9f4b\u85e4 \u8aa0\u3001\u77f3\u5802\u4f73\u4e16\u3001\u5b89\u7530\u6709\u7406\u3001\u5712\u539f\u4e00\u6075\u3001\u4e2d\u6751\u6587\u9999\u3001\u7530\u5730\u4f73\u5948\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u8328\u57ce\u770c \u304c\u3093\u8a3a\u7642\u306e\u57fa\u5e79\u75c5\u9662\u306b\u304a\u3051\u308b\u30b2\u30ce\u30e0\u533b\u7642\u4f53\u5236\u306e\u6574\u5099\u3068\u8ab2\u984c\u2015\u4e73\u817a\u5916\u6765\u306e\u907a\u4f1d\u6027\u4e73\u764c\u8a3a\u7642\u3078\u306e\u53d6\u308a\u7d44 \u307f\uff0e\u7b2c 27 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7(\u6771\u4eac)<\/li>\n\n\n\n
                        7. \u6e21\u8fba\u9686\u7d00\u3001\u5411\u4e95\u535a\u6587\u3001\u6734 \u82f1\u9032\u3001\u9ad8\u6a4b\u5c06\u4eba\u3001\u76f8\u826f\u5b89\u662d\u3001\u897f\u6751\u4ee4\u559c\u3001\u9ad8\u5cf6\u52c9\u3001\u85e4\u6fa4\u77e5\u5df3\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u8ee2\u79fb\u30fb\u518d\u767a\u4e73\u764c\u306b\u5bfe\u3059\u308b\u30a2\u30f3\u30b9\u30e9\u30b5\u30a4\u30af\u30ea\u30f3\u7cfb\u85ac\u5264\u3068 S-1 \u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\uff08SELECTBCCONFIRM\uff09\uff0e\u7b2c 27 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7(\u6771\u4eac)<\/li>\n\n\n\n
                        8. \u9ad8\u5cf6 \u52c9\u3001\u5411\u4e95\u535a\u6587\u3001\u4e0a\u6751\u6709\u9999\u91cc\u3001\u8d64\u7fbd\u5f18\u5145\u3001\u6e21\u8fba\u9686\u7d00\u3001\u6734 \u82f1\u9032\u3001\u9ad8\u6a4b\u5c06\u4eba\u3001\u76f8\u826f\u5b89\u662d\u3001\u897f\u6751\u4ee4\u559c\u3001\u85e4\u6fa4\u77e5\u5df3\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u518d\u767a\u4e73\u764c 1 \u6b21\u5316\u5b66\u7642\u6cd5\u3068\u3057\u3066\u306e\u30a2\u30f3\u30b9\u30e9\u30b5\u30a4\u30af\u30ea\u30f3\u307e\u305f\u306f\u30bf\u30ad\u30b5\u30f3\u3068 S1 \u306e\u6bd4\u8f03\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10(\u798f\u5ca1)<\/li>\n\n\n\n
                        9. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u7af9\u5185\u76f4\u4eba\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u9ad8\u6a4b\u77e5\u5b50\u3001\u5712\u539f\u4e00\u6075\uff0e\u521d\u8a3a\u6642\u306b\u6551\u6025\u642c\u9001\u3055\u308c\u305f\u4e73\u764c \u75c7\u4f8b\u306e\u691c\u8a0e\uff0e\u7b2c 58 \u56de\u5168\u56fd\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a\u30012019.10(\u5fb3\u5cf6)<\/li>\n\n\n\n
                        10. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u7af9\u5185\u76f4\u4eba\u3001\u77f3\u9ed2\u614e\u543e\u3001\u4e09\u6a4b\u5f70\u4e00\u3001\u98ef\u5cf6\u9054\u751f\uff0e\u598a\u5a20\u95a2\u9023\u4e73\u764c 3 \u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u7d4c\u9a13\uff0e\u7b2c 81 \u56de\u65e5\u672c\u81e8\u5e8a\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012019.11(\u9ad8\u77e5)<\/li>\n\n\n\n
                        11. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u7af9\u5185\u76f4\u4eba\u3001\u753a\u6c38\u5e79\u6708\u3001\u6e21\u908a\u4f91\u5948\u3001\u658e\u85e4\u4ec1\u662d\u3001\u98ef\u5cf6\u9054\u751f\u3001\u9ad8\u6a4b\u77e5\u5b50\u3001\u5712\u539f\u4e00\u6075\uff0e\u521d\u671f\u6cbb\u7642\u304b\u3089 10 \u5e74\u5f8c\u306b\u6e29\u5b58\u4e73\u623f\u5185\u4e73\u982d\u306b\u9650\u5c40\u3057\u305f\u6d78\u6f64\u6027\u4e73\u7ba1\u764c\u304c\u767a\u751f\u3057\u305f 1 \u4f8b\u30012019.12(\u3055\u3044\u305f\u307e)<\/li>\n\n\n\n
                        12. \u753a\u6c38\u5e79\u6708\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7af9\u5185\u76f4\u4eba\u3001\u658e\u85e4\u4ec1\u662d\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u8840\u6027\u7570\u5e38\u4e73\u982d\u5206\u6ccc\u3092\u5448\u3057\u4e73\u982d\u5168\u5207\u9664\u8853\u3092\u65bd\u884c\u3057\u305f Nipple adenoma \u306e\uff11\u4f8b\uff0e2019.12(\u3055\u3044\u305f\u307e)<\/li>\n\n\n\n
                        13. \u7af9\u5185\u76f4\u4eba\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u658e\u85e4\u4ec1\u662d\uff0e\u8853\u5f8c\u653e\u5c04\u7dda\u7642\u6cd5\u306b\u3088\u308a\uff15\u5e74\u9593\u7121\u518d\u767a\u306e\u5f8c\u3001\u6025\u6fc0\u306a\u8ee2 \u5e30\u3092\u304d\u305f\u3057\u305f\u975e\u6d78\u6f64\u764c\u65ad\u7aef\u967d\u6027\u306e\u4e00\u4f8b\uff0e2019.12(\u3055\u3044\u305f\u307e)<\/li>\n\n\n\n
                        14. \u5712\u539f\u4e00\u6075\u3001\u6d77\u8001\u6839\u8056\u5b50\u3001\u4e0a\u91ce\u6f84\u6075\u3001\u9ad8\u6a4b\u77e5\u5b50\u3001\u83ca\u6c60\u4e07\u7406\u6075\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001 \u7af9\u5185\u76f4\u4eba\u3001\u658e\u85e4\u9ad8\u3001\u677e\u6728 \u85ab\uff0e\u5de8\u5927\u81ea\u58ca\u5275\u3092\u4f34\u3046 T4 \u4e73\u304c\u3093\u60a3\u8005\u306e ACP \u5b9f\u8df5\u306e\u4e00\u4e8b\u4f8b\uff0e2019.12(\u3055\u3044\u305f\u307e)<\/li>\n<\/ol>\n\n\n\n

                          \u3010\u53f8\u4f1a\u3011<\/p>\n\n\n\n

                            \n
                          1. \u30dd\u30b9\u30bf\u30fc\u30bb\u30c3\u30b7\u30e7\u30f3\uff08109\uff09\u300c\u4e73\u817a-\u5206\u5b50\u6a19\u7684\u85ac\u30fb\u5468\u8853\u671f\u7ba1\u7406\u300d\uff0e\u7b2c 119 \u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a\u30012019.4(\u5927\u962a)<\/li>\n\n\n\n
                          2. \u30c7\u30b8\u30bf\u30eb\u30dd\u30b9\u30bf\u30fc85 \u30aa\u30f3\u30b3\u30d7\u30e9\u30b9\u30c6\u30a3\u30c3\u30af\u30b5\u30fc\u30b8\u30e3\u30ea\u30fc\uff1a\u4e73\u623f\u518d\u5efa\u2463\uff0e\u7b2c 27 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012019.7(\u6771\u4eac)<\/li>\n\n\n\n
                          3. \u4e00\u822c\u6f14\u984c\uff08\u30dd\u30b9\u30bf\u30fc\uff09\u7532\u72b6\u817a 18\uff0e\u7b2c 52 \u56de\u65e5\u672c\u5185\u5206\u6ccc\u5916\u79d1\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30012019.10(\u6771\u4eac)<\/li>\n<\/ol>\n\n\n\n

                            \u5e73\u621030\u5e74\u5ea6<\/h3>\n\n\n\n

                            \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                              \n
                            1. Kitahara M, Hozumi Y, Watanabe A, Iijima T. Bowen’s Disease of the Nipple. Case Rep Oncol. 11, 609-614. 2018.<\/li>\n\n\n\n
                            2. Kitahara M, Hozumi Y, Asada R, Sawa A, Saito H, Iijima T. Intramammary Metastasis in a Patient with a History of Renal Cell Carcinoma: A Case Report. Case Rep Oncol. 11, 318- 322. 2018.<\/li>\n<\/ol>\n\n\n\n

                              \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                \n
                              1. Park Y, Akabane H, Watanabe T, Takahashi M, Sagara Y, Nishimura R, Tsurutani J, Takashima T, Fujisawa T, Hozumi Y, Uemura Y, Mukai H Randomized phase 3 study of anthracyclinecontaining regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BCCONFIRM) A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC) San Antonio Breast Cancer Symposium, 2018. Dec 5 San Antonio, TX, USA<\/li>\n\n\n\n
                              2. Ohtani S, Iijima K, Higaki K, Sato Y, Hozumi Y, Hasegawa Y, Takei H, Tanaka M, Yagata H, Masuoka H, Tanabe M, Egawa C, Komoike Y, Saji S, Nakamura T, Yanagita Y, Ohtsu H, Mukai H, Iwase T. A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years – Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS). San Antonio Breast Cancer Symposium, 2018. Dec 6 San Antonio, TX, USA<\/li>\n\n\n\n
                              3. \u5712\u539f\u4e00\u6075\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u6fa4\u6587\u3001\u7389\u7530\u5d69\u548c\u3001\u7a42\u7a4d\u5eb7\u592b. \u4eba\u5de5\u4e73\u623f\u518d\u5efa\u3092\u53d7\u3051\u305f\u60a3\u8005\u304b\u3089\u898b\u3048\u305f\u5404\u6642\u671f\u306b\u304a\u3051\u308b\u751f\u6d3b\u6307\u5c0e\u306e\u691c\u8a0e. \u7b2c 26 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012018. 5\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n
                              4. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u6fa4\u6587\u3001\u5712\u539f\u4e00\u6075. \u7cbe\u795e\u79d1\u533b\u4e0d\u5728\u306e\u5f53\u9662\u306b\u304a\u3051\u308b\u7cbe\u795e\u75be\u60a3\u5408\u4f75\u4e73\u764c\u624b\u8853\u75c7\u4f8b\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c 26 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012018. 5\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n
                              5. \u6fa4\u6587\u3001\u671d\u7530\u7406\u592e\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u5712\u539f\u4e00\u6075\u3001\u5b89\u7530\u6709\u7406\u3001\u9f4b\u85e4\u8aa0\u3001\u7a42\u7a4d\u5eb7\u592b. \u8853\u5f8c 1 \u5e74\u76ee\u306b\u5bfe\u5074\u4e73\u764c\u3092\u767a\u75c7\u3057\u305f\u4e21\u5074\u591a\u767a\u7570\u6642\u6027\u4e73\u764c\u3088\u308a\u8a3a\u65ad\u3055\u308c\u305f\u907a\u4f1d\u6027\u4e73\u764c\u5375\u5de3\u764c\u75c7\u5019\u7fa4\u306e\u4e00\u4f8b. \u7b2c 26 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012018 .5\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n
                              6. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u671d\u7530\u7406\u592e. \u7cbe\u795e\u75be\u60a3\u3092\u5408\u4f75\u3059\u308b\u4e73\u764c\u624b\u8853\u75c7\u4f8b\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c 118 \u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a\u30012018. 4\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n
                              7. \u6fa4\u6587\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u98ef\u5cf6\u9054\u751f\u3001\u6589\u85e4\u4ec1\u662d\u3001\u9234\u6728\u7ae0\u53f2\u3001\u7a42\u7a4d\u5eb7\u592b. \u7532\u72b6\u817a\u4e73\u982d\u764c\u3092\u5408\u4f75\u3057\u305f black thyroid \u306e
                                \u4e00\u4f8b. \u7b2c 30 \u56de\u65e5\u672c\u5185\u5206\u6ccc\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012018. 8\uff08\u672d\u5e4c\uff09<\/li>\n\n\n\n
                              8. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u4e2d\u6751\u6587\u9999\u3001\u7530\u5730\u4f73\u90a3\u3001\u6589\u85e4\u4ec1\u662d\u3001\u98ef\u5cf6\u9054\u751f\u3001\u7a42\u7a4d\u5eb7\u592b. \u809d\u8ee2\u79fb\u5de3\u3067 HER2 \u967d\u8ee2\u5316\u3092\u307f\u3068\u3081\u305f\u6669\u671f\u518d\u767a\u4e73\u764c\u306e 1 \u4f8b. \u7b2c 15 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012018. 12(\u3055\u3044\u305f\u307e)<\/li>\n\n\n\n
                              9. \u7530\u5730\u4f73\u90a3\u3001\u4e2d\u6751\u6587\u9999\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b . \u96c6 \u5b66 \u7684 \u6cbb \u7642 \u53ca \u3073 3rd line \u3067 \u306eLapatinib+Capecitabine \u3067\u826f\u597d\u306a\u5236\u5fa1\u3092\u5f97\u305f HER2 \u967d\u6027\u8ee2\u79fb\u30fb\u518d\u767a\u4e73\u764c\u306e\u4e00\u4f8b. \u7b2c 15 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u3001 2018.12(\u3055\u3044\u305f\u307e)<\/li>\n<\/ol>\n\n\n\n

                                \u5e73\u621029\u5e74\u5ea6<\/h3>\n\n\n\n

                                \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                                  \n
                                1. Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Mukai H, Yasuda Y. Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett, 13:1731-1740, 2017<\/li>\n\n\n\n
                                2. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H, Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC Cancer, 17:773-782, 2017<\/li>\n\n\n\n
                                3. Fujii S, Yamashita S, Yamaguchi T, Takahashi M, Hozumi Y, Ushijima T, Mukai H. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. Oncotarget, 8:19039-19048, 2017<\/li>\n\n\n\n
                                4. \u5317\u539f\u7f8e\u7531\u7d00, \u7a42\u7a4d\u5eb7\u592b, \u677e\u5c3e\u77e5\u5e73, \u5869\u6fa4\u5e79\u96c4, \u6589\u85e4\u4ec1\u662d, \u98ef\u5cf6\u9054\u751f, \u9ad8\u5c3e\u5e79\u4e5f, \u963f\u90e8\u79c0\u6a39\uff1a\u539f\u767a\u6027\u809d\u764c\u3068\u306e\u9451 \u5225\u3092\u8981\u3057\u6cbb\u7642\u65b9\u91dd\u6c7a\u5b9a\u306b\u809d\u751f\u691c\u304c\u6709\u7528\u3067\u3042\u3063\u305f\u4e73\u764c\u8853\u5f8c\u809d\u8ee2\u79fb\u306e 1 \u4f8b \u4e73\u764c\u8853\u5f8c \u8ee2\u79fb\u7591\u75c5\u5909\u306b\u5bfe\u3059\u308b\u751f\u691c \u6642\u306b\u8003\u616e\u3059\u3079\u304d\u4e8b\u9805\u3001\u4e73\u764c\u306e\u81e8\u5e8a\u300132:157-165, 2017.<\/li>\n\n\n\n
                                5. \u7530\u4e2d\u88d5\u7f8e\u5b50, \u85e4\u7530\u5d07\u53f2, \u829d \u8061\u7f8e, \u897f\u7530\u7d17\u5b63, \u5bae\u5d0e\u5343\u7d75\u5b50, \u6afb\u6728\u96c5\u5b50, \u68ee\u7530\u525b\u5e73, \u4ec1\u6728\u5229\u90ce, \u5c3e\u672c\u304d\u3088\u304b, \u8efd\u90e8 \u771f\u7ca7\u7f8e, \u7a42\u7a4d\u5eb7\u592b, \u30a2\u30e9\u30f3 K.\u30fb\u30ec\u30d5\u30a9\u30fc , \u4f50\u7530\u5c1a\u5b8f\uff1a\u814b\u7aa9\u30ea\u30f3\u30d1\u7bc0\u816b\u5927\u3092\u8a8d\u3081\u305f\u826f\u6027\u4e73\u817a\u9846\u7c92\u7d30\u80de\u816b\u306e 1 \u75c7\u4f8b\u3001\u4e73\u764c\u306e\u81e8\u5e8a 32:59-65, 2017.<\/li>\n<\/ol>\n\n\n\n

                                  \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                    \n
                                  1. \u677e\u5c3e\u77e5\u5e73\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5742\u6771\u88d5\u5b50\u3001\u539f\u5c1a\u4eba\u3001 \u9ad8\u9f62\u8005\u4e73\u764c\u60a3\u8005\u306b\u5bfe\u3059\u308b\u5916\u79d1\u7684\u6cbb\u7642\u306e\u691c\u8a0e\u3001\u7b2c 117 \u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 4\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n
                                  2. \u5bfa\u5d0e\u6893\u3001\u5742\u6771\u88d5\u5b50\u3001\u9ad8\u6728\u7406\u592e\u3001\u661f\u8475\u3001\u6a4b\u672c\u5e78\u679d\u3001\u7530\u5730\u4f73\u90a3\u3001\u5e02\u5ca1\u6075\u7f8e\u9999\u3001\u6d25\u5cf6\u7531\u5e0c\u5b50\u3001\u6c60\u7530\u9054\u5f66\u3001\u4e95\u53e3\u7814\u5b50\u3001 \u7a42\u7a4d\u5eb7\u592b\u3001\u539f\u5c1a\u4eba\u3001\u4e73\u764c\u8853\u524d\u5316\u5b66\u7642\u6cd5\u5f8c\u306e\u75c5\u7406\u5b66\u7684\u5b8c\u5168\u594f\u529f\u4e88\u6e2c\u306e\u8a55\u4fa1\u3001\u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 7\uff08\u798f \u5ca1\uff09<\/li>\n\n\n\n
                                  3. \u5c71\u672c\u8c4a\u3001\u897f\u6751\u4ee4\u559c\u3001\u6210\u4e95\u4e00\u9686\u3001\u559c\u5cf6\u7950\u5b50\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u6c60\u7530\u96c5\u5f66\u3001\u9ad8\u5c3e\u4fe1\u592a\u6717\u3001\u5927\u8c37\u5f70\u4e00\u90ce\u3001\u5ca9\u702c\u5f18\u656c\u3001AI \u62b5 \u6297\u6027\u306e\u9032\u884c\u30fb\u518d\u767a\u4e73\u764c\u3092\u5bfe\u8c61\u3068\u3057\u305f\u9ad8\u7528\u91cf\u30c8\u30ec\u30df\u30d5\u30a7\u30f3\u3068\u30d5\u30eb\u30d9\u30b9\u30c8\u30e9\u30f3\u30c8\u306e\u7121\u4f5c\u70ba\u5316\u7b2c\u4e8c\u76f8\u8a66\u9a13\u3001\u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 7\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n
                                  4. \u5712\u539f\u4e00\u6075\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5869\u6fa4\u5e79\u96c4\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u4f50\u3005\u6728\u5553\u592a\u3001\u5c40\u6240\u9032\u884c\u4e73\u304c\u3093\u60a3\u8005\u306e\u53d7\u8a3a\u9045\u5ef6\u8981\u56e0\u306b\u5bfe\u3059\u308b\u30c1 \u30fc\u30e0\u30a2\u30d7\u30ed\u30fc\u30c1\u3001\u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 7\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n
                                  5. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u4f50\u3005\u6728\u5553\u592a\u3001\u5869\u6fa4\u5e79\u96c4\u3001\u5712\u539f\u4e00\u6075\u3001\u5f53\u9662\u306b\u304a\u3051\u308b T4 \u4e73\u764c\u75c7\u4f8b\u306e\u81e8\u5e8a\u75c5\u7406\u5b66\u7684\u691c\u8a0e\u3001 \u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 7\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n
                                  6. \u6afb\u6728\u96c5\u5b50\u3001\u5e73\u5e78\u8f1d\u3001\u7530\u4e2d\u88d5\u7f8e\u5b50\u3001 \u829d\u8061\u7f8e\u3001 \u5bae\u5d0e\u5343\u7d75\u5b50\u3001 \u5869\u6fa4\u5e79\u96c4\u3001\u7af9\u5185\u8b77, \u85e4\u7530\u5d07\u53f2\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u4f50\u7530\u5c1a \u5b8f\u3001\u8208\u68a0\u8cb4\u82f1\u3001\u4e09\u91cd\u91ce\u7267\u5b50\u3001\u6c34\u6cbc\u6d0b\u6587\u3001\u4e73\u764c\u624b\u8853\u306b\u304a\u3051\u308b PONV(\u8853\u5f8c\u60aa\u5fc3\u30fb\u5614\u5410)\u767a\u751f\u306e\u691c\u8a0e \u30c7\u30ad\u30b5\u30e1\u30bf\u30be\u30f3\u306e\u4e88\u9632\u6295\u4e0e\u306f\u6709\u52b9\u304b? \u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017.7\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n
                                  7. \u7a42\u7a4d\u5eb7\u592b\u3001\u9ad8\u6a4b\u5c06\u4eba\u3001\u85e4\u6fa4\u77e5\u5df3\u3001\u7c73\u5c71\u516c\u5eb7\u3001\u5927\u4f4f\u7701\u4e09\u3001\u8d64\u7fbd\u5f18\u5145\u3001\u897f\u6751\u4ee4\u559c\u3001\u9ad8\u5cf6\u52c9\u3001\u76f8\u826f\u5b89\u662d\u3001\u4e95\u672c \u6ecb\u3001\u5411\u4e95\u535a\u6587\u3001HER2 \u967d\u6027\u4e73\u764c\u306b\u5bfe\u3057\u3066\u8853\u524d\u5316\u5b66\u7642\u6cd5\u304c\u624b\u8853\u306b\u53ca\u307c\u3059\u5f71\u97ff Ki67 index \u3092\u7528\u3044\u305f\u6cbb\u7642\u9078\u629e \u7814\u7a76\u306e\u5916\u79d1\u4ed8\u968f\u7814\u7a76\u3001\u7b2c 25 \u56de\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012017. 7\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n
                                  8. \u671d\u7530\u7406\u592e\u3001\u4f50\u3005\u6728\u5553\u592a\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u4e73\u764c\u521d\u8a3a\u6642\u306b\u773c\u7aa9\u8ee2\u79fb\u3092\u8a8d\u3081\u305f\u4e00\u4f8b\u3001\u7b2c 14 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012017. 12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n\n\n\n
                                  9. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u671d\u7530\u7406\u592e\u3001\u814e\u7d30\u80de\u764c\u53ca\u3073\u4e73\u764c\u8853\u5f8c\u306b\u51fa\u73fe\u3057\u305f\u591a\u767a\u80ba\u8ee2\u79fb\u5de3\u306e\u81ea\u7136\u6d88\u9000\u3068\u5b64\u7acb\u6027\u4e73 \u623f\u5185\u8ee2\u79fb\u3092\u304d\u305f\u3057\u305f\u4e00\u4f8b\u3001\u7b2c 14 \u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012017. 12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n\n\n\n
                                  10. \u6e21\u908a\u660e\u6075\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u4f50\u3005\u6728\u5553\u592a\u3001\u671d\u7530\u7406\u592e\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u4e73\u982d\u90e8\u306b\u767a\u751f\u3057\u305f Bowen \u75c5\u306e1\u4f8b\u3001\u7b2c14\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012017. 12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n\n\n\n
                                  11. \u698e\u6238\u7fe0\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u4e0a\u5927\u9759\u8108\u3078\u306e\u816b\u760d\u585e\u6813\u3092\u304d\u305f\u3057\u305f\u518d\u767a\u4e73\u764c\u306e 1 \u75c7\u4f8b\u3001\u7b2c14\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012017. 12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n\n\n\n
                                  12. Nishimura R, Yamamoto Y, Narui K, kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S, Iwase H, A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior nonsteroidal aromatase nhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study), San Antonio Breast Cancer Symposium, 2017.12 (San Antonio, TX, USA)<\/li>\n<\/ol>\n\n\n\n

                                    \u5e73\u621028\u5e74\u5ea6<\/h3>\n\n\n\n

                                    \u3010\u8457\u66f8\u3011<\/p>\n\n\n\n

                                      \n
                                    1. \u7a42\u7a4d\u5eb7\u592b\uff1a\u7b2cII\u7ae0\u4e73\u764c\u85ac\u7269\u7642\u6cd5\u306e\u5b9f\u969b\u3000\u8853\u5f8c\u5185\u5206\u6ccc\u7642\u6cd5\u6295\u4e0e\u671f\u9593\uff0e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u30af\u30ea\u30cb\u30ab\u30eb\u30ac\u30a4\u30c9\u4e73\u764c\u85ac\u7269\u7642\u6cd5\uff08\u6728\u4e0b\u8cb4\u4e4b\u3001\u6238\u4e95\u96c5\u548c\u7de8\uff09p155-159\uff0c2016<\/li>\n<\/ol>\n\n\n\n

                                      \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                                        \n
                                      1. Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Yasuda Y. Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncology Letters, 13(3): 1731-1740, 2017<\/li>\n\n\n\n
                                      2. Fujii S, Yamashita S, Yamaguchi T, Takahashi M, Hozumi Y, Ushijima T, Mukai H. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. Oncotarget, 8(12): 19039-19048, 2017<\/li>\n\n\n\n
                                      3. Mukai H, Kato K, Esaki T, Ohsumi S, Hozumi Y, Matsubara N, Hamaguchi T, Matsumura Y, Goda R, Hirai T, Nambu Y. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Investigational new drugs, 34(6): 750-759, 2016.<\/li>\n\n\n\n
                                      4. Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Hozumi Y, Sata N, Ito Y. Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer. PLoS One, 11(9): e0162616, 2016<\/li>\n\n\n\n
                                      5. Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Hozumi Y, Yasuda Y, Hatake K. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today, 46(7): 821-6, 2016 7.\u3000<\/li>\n\n\n\n
                                      6. \u7530\u4e2d\u88d5\u7f8e\u5b50, \u85e4\u7530\u5d07\u53f2, \u829d\u8061\u7f8e, \u897f\u7530\u7d17\u5b63, \u5bae\u5d0e\u5343\u7d75\u5b50, \u6afb\u6728\u96c5\u5b50, \u68ee\u7530\u525b\u5e73, \u4ec1\u6728\u5229\u90ce, \u5c3e\u672c\u304d\u3088\u304b, \u8efd\u90e8\u771f\u7ca7\u7f8e, \u30a2\u30e9\u30f3K.\u30ec\u30d5\u30a9\u30fc,\u7a42\u7a4d\u5eb7\u592b, \u4f50\u7530\u5c1a\u5b8f\uff1a\u814b\u7aa9\u30ea\u30f3\u30d1\u7bc0\u816b\u5927\u3092\u8a8d\u3081\u305f\u826f\u6027\u4e73\u817a\u9846\u7c92\u7d30\u80de\u816b\u306e\uff11\u75c7\u4f8b. \u4e73\u764c\u306e\u81e8\u5e8a32(1): 59-65, 2017<\/li>\n<\/ol>\n\n\n\n

                                        \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                          \n
                                        1. \u7a42\u7a4d\u5eb7\u592b\u3001\u6e21\u908a\u77e5\u6620\u3001\u6b66\u4e95\u5bdb\u5e78\u3001\u5411\u4e95\u535a\u6587\u3001\u4e2d\u6751\u6e05\u543e\uff0eQuality Indicator\u3092\u7528\u3044\u305f\u4e73\u764c\u8a3a\u7642\u306e\u8a55\u4fa1\uff0e\u7b2c24\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u7dcf\u4f1a\u3000\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u30012016.6\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n
                                        2. \u5411\u4e95\u535a\u6587\u3001\u5c71\u53e3\u96c4\u3001\u9ad8\u6a4b\u5c06\u4eba\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u85e4\u6fa4\u77e5\u5df3\u3001\u5927\u7af9\u7701\u4e09\u3001\u8d64\u7fbd\u5f18\u5145\u3001\u897f\u6751\u4ee4\u559c \u9ad8\u5cf6\u52c9, \u6734\u82f1\u9032, \u76f8\u826f\u5b89\u662d, \u9060\u5c71\u7adc\u4e5f, \u4e95\u672c\u6ecb, \u6c34\u91ce\u8061\u6717, \u4e0a\u6751\u5915\u9999\u7406\uff0e\u764c\u306b\u5bfe\u3059\u308b\u30d7\u30ec\u30b7\u30b8\u30e7\u30f3\u30e1\u30c7\u30a3\u30b7\u30f3 Ki-67 index\u3092\u7528\u3044\u305fHER2\u967d\u6027\u4e73\u764c\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u9078\u629e\u7814\u7a76\uff0e\u7b2c54\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012016.10\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n
                                        3. Shiroiwa, T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost Effectiveness of first line S-1 therapy for metastatic breast cancer patients compared with taxanes: An analysis based on the randomized phase III Select BC Trial. ISPOR 19th<\/sup> Annual European Congress, 2016.11 (Vienna, Austria)<\/li>\n\n\n\n
                                        4. \u677e\u5c3e\u77e5\u5e73\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\uff0e\u80f8\u9aa8\u8ee2\u79fb\u306e\u78ba\u5b9a\u8a3a\u65ad\u306bCT\u30ac\u30a4\u30c9\u4e0b\u751f\u691c\u304c\u6709\u7528\u3067\u3042\u3063\u305f1\u4f8b\uff0e\u7b2c13\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012016.12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n\n\n\n
                                        5. \u5317\u539f\u7f8e\u7531\u7d00\u3001\u7a42\u7a4d\u5eb7\u592b\u3001\u677e\u5c3e\u77e5\u5e73\u3001\u5869\u6fa4\u5e79\u96c4\uff0e\u539f\u767a\u6027\u809d\u816b\u760d\u3068\u306e\u9451\u5225\u3092\u8981\u3057\u6cbb\u7642\u65b9\u91dd\u6c7a\u5b9a\u306b\u809d\u751f\u691c\u304c\u6709\u7528\u3067\u3042\u3063\u305f\u4e73\u764c\u8853\u5f8c\u809d\u8ee2\u79fb\u306e1\u4f8b\uff0e\u7b2c13\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u30012016.12\uff08\u3055\u3044\u305f\u307e\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                                          \u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6 \u4ee4\u548c6\u5e74\u5ea6 \u3010\u81e8\u5e8a\u7814\u7a76\u3011 \u4ee4\u548c5\u5e74\u5ea6 \u3010\u82f1\u6587\u539f\u8457\u3011 \u3010\u548c\u6587\u3011 \u4ee4\u548c4\u5e74\u5ea6 \u3010\u82f1\u6587\u539f\u8457\u3011 \u3010\u548c\u6587\u3011 \u4ee4\u548c3\u5e74\u5ea6 \u3010\u82f1\u6587\u539f\u8457\u3011 \u3010\u548c\u6587\u3011 \u4ee4\u548c2\u5e74\u5ea6 \u3010\u82f1\u6587\u539f\u8457\u3011 \u3010\u548c\u6587\u7dcf\u8aac\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c\u5143 […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":790,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"vk-ltc-link":"","vk-ltc-target":"0","footnotes":""},"class_list":["post-16785","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=16785"}],"version-history":[{"count":5,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16785\/revisions"}],"predecessor-version":[{"id":25098,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16785\/revisions\/25098"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/790"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=16785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}